Skip to main content
Top
Published in: Allergy, Asthma & Clinical Immunology 2/2014

Open Access 01-12-2014 | Meeting abstract

The observed incidence of anaphylaxis and serum sickness in patients receiving omalizumab in a tertiary allergy and asthma clinic in Canada

Authors: Megan MacRae, Stephanie Santucci, Jacob Karsh, William H Yang

Published in: Allergy, Asthma & Clinical Immunology | Special Issue 2/2014

Login to get access

Excerpt

In a post-marketing analysis last updated in July 2007, the FDA reported that an estimated 0.2% of patients suffered treatment related anaphylaxis and rare incidence of serum sickness. To substantiate this, the occurrence of treatment related anaphylaxis and serum sickness in our large Canadian allergy and asthma tertiary clinic was assessed. …
Metadata
Title
The observed incidence of anaphylaxis and serum sickness in patients receiving omalizumab in a tertiary allergy and asthma clinic in Canada
Authors
Megan MacRae
Stephanie Santucci
Jacob Karsh
William H Yang
Publication date
01-12-2014
Publisher
BioMed Central
DOI
https://doi.org/10.1186/1710-1492-10-S2-A28

Other articles of this Special Issue 2/2014

Allergy, Asthma & Clinical Immunology 2/2014 Go to the issue